Oct 11, 2012

Why We Should be Hopeful about Solanezumab

There are a lot of talented people out there working on Alzheimer's and searching for an effective treatment. More than you might think.

By Bob DeMarco 
 Alzheimer's Reading Room

Why We Should be Hopeful about Solanezumab
You probably saw the headlines that two Phase 3 clinical trial for Solanezumab failed. True enough. Not enough evidence to get FDA approval for the drug.

But. As I was watching the Cure Alzheimer's Fund Symposium, Taking Control of Alzheimer's Through Research: The Road Map to Therapies, my eyes popped open when Rudy Tanzi explained that there was more than meets the eye in the studies findings, and that inside the results there is a lot of positive news.

Lets skip to the skinny. Solanezumab did show promise of slowing Alzheimer's in a certain subset of the population studied.

Solanezumab is an experimental, humanized antibody that binds to soluble ß-amyloid and thereby may draw the peptide away from the brain through the blood. This could reduce the formation of amyloid plaque seen in the brains of patients with Alzheimer’s disease and hypothesized to kill brain cells.

The key word, ß-amyloid. The study confrims that scientist are looking in the right place. Or, one of the right places for a treatment for Alzheimer's.

Now, I am not doctor or a scientist, but I couldn't help wondering. What if Solanezumab does slow down cognitive decline a bit? Well, we won't find that out for a couple of more years.

Then I though, what if Solanezumab was married with lets say -- Namenda. What if the combination therapy worked better than one we have today. As most of you know, I am a fan of the combination of Aricept and Namenda. So what if there was some combination of Solanezumab, Aricept, and/or Namenda that worked to slow memory loss or cognitive decline?

Now this my friends gives me hope.

Before I forget, there are some top notch scientist that believe we could have a treatment for Alzheimer's within five years. I'll get to that in another article.

For those of you who are the naysayers -- ba humbug. They said statins would never work, and what about a vaccine for polio? They said it couldn't be done.

There are a lot of talented people out there working on Alzheimer's and searching for an effective treatment. The scientists backed by the Cure Alzheimer's Fund are collaborating which is the best approach. Sharing intellectual capital.

Take a look at the video below to get a better understanding of Solanezumab and the current findings.

Visit NBCNews.com for breaking news, world news, and news about the economy
Bob DeMarco
Bob DeMarco is the Founder of the Alzheimer's Reading Room and an Alzheimer's caregiver. The ARR knowledge base contains more than 3,811 articles with more than 306,100 links on the Internet. Bob lives in Delray Beach, FL.
Original content Bob DeMarco, the Alzheimer's Reading Room